Stephen Hoffman

TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts.

Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California.

PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA.

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA.

Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA.

TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA.

Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO.

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.

Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA.

Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.

Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA.

Research Alliance Corp. II operates as a blank check company. The company was founded by Peter Kolchinsky, Matthew Hammond and Tess Cameron on July 17, 2020 and is headquartered in Las Vegas, NV.

Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA.

BYOMass, Inc. provides investment holding services. The company is headquartered in Sudbury, MA.

Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia.